Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.50 USD
-0.14 (-8.54%)
Updated May 28, 2024 04:00 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 381 - 394 ( 394 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
We initiate coverage with a Buy rating and a $10 target.
Provider: Roth Capital Partners, Inc.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Life Sciences -MAC Best Ideas Conference - Key Takeaways New York City.
Provider: WEDBUSH SECURITIES INC.
Company: Nektar Therapeutics
Industry: Medical - Drugs
We See Further Upside This Year Linked to a NKTR-102 Collaboration.
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P
Company: Nektar Therapeutics
Industry: Medical - Drugs
PECIALTY PHARMACEUTICALS:Do Your Homework Over the Summer Because the Fall Will Be Explosive with Major PDUFA Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P
Company: Nektar Therapeutics
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Nektar Therapeutics
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Nektar Therapeutics
Industry: Medical - Drugs
Tour Guide to ASCO 2010-Our Take on the (Many) Abstracts of Interest.
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P